Japan-marketed larotrectinib is effective for patients with locally advanced or metastatic solid tumors carrying NTRK fusion gene mutations. Larotrectinib is a targeted agent for the treatment of adult and pediatric patients with advanced solid tumors with fusion mutations in the NTRK genes (NTRK1, NTRK2, NTRK3).Based on data from the three clinical trials, LOXO-TRK-14001, SCOUT, and NAVIGATE, the overall efficacy rate of larotrectinib in more than a dozen types of cancers was 75%, with 22% of the patients in complete remission and 53% partial remission. Lalotinib must be tested for NTRK gene before use, there may be side effects such as fatigue, nausea, dizziness in the process of using the drug, it is forbidden for those who are allergic to the drug, and it is necessary to review regularly in the course of the treatment, so the patients must apply under the guidance of the doctor, and should not use it on their own.